Caribou Biosciences (NASDAQ:CRBU) Releases Earnings Results

Caribou Biosciences (NASDAQ:CRBU) announced its earnings results on Thursday. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.05, FiscalAI reports. Caribou Biosciences had a negative net margin of 1,327.40% and a negative return on equity of 72.48%. The company had revenue of $3.94 million for the quarter, compared to analyst estimates of $1.96 million.

Caribou Biosciences Stock Performance

NASDAQ:CRBU traded up $0.11 on Friday, hitting $1.82. 1,291,940 shares of the stock were exchanged, compared to its average volume of 1,324,719. Caribou Biosciences has a 52 week low of $0.66 and a 52 week high of $3.54. The stock has a market capitalization of $170.12 million, a price-to-earnings ratio of -1.14 and a beta of 2.54. The company’s 50-day moving average price is $1.64 and its 200 day moving average price is $1.90.

Institutional Investors Weigh In On Caribou Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of CRBU. Squarepoint Ops LLC raised its position in shares of Caribou Biosciences by 132.0% during the 4th quarter. Squarepoint Ops LLC now owns 55,938 shares of the company’s stock valued at $89,000 after acquiring an additional 31,828 shares during the last quarter. Qube Research & Technologies Ltd bought a new position in shares of Caribou Biosciences in the 3rd quarter worth $105,000. Credit Agricole S A acquired a new stake in shares of Caribou Biosciences during the third quarter worth $68,000. Jefferies Financial Group Inc. acquired a new stake in shares of Caribou Biosciences during the third quarter worth $110,000. Finally, US Bancorp DE increased its holdings in Caribou Biosciences by 18,624.0% in the third quarter. US Bancorp DE now owns 34,265 shares of the company’s stock valued at $80,000 after purchasing an additional 34,082 shares during the last quarter. 77.51% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Caribou Biosciences in a research report on Wednesday, January 21st. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $8.00.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company’s core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.

Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology.